TMCI earnings analysis
What we found in TMCI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Treace Medical Concepts reported a decrease in Q1 2026 revenue to $47.2 million, missing estimates of $46.0 million, along with a wider net loss of $(18.0) million, or EPS of $(0.28). The company continues to face operational challenges, maintaining full-year revenue guidance of $202 million to $212 million amid a competitive and challenging economic environment.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue Decline
- Revenue fell 10.2% YoY to $47.2M from $52.6M in Q1 2025.
- Wider Net Loss
- Net loss increased to $(18.0) million or $(0.28) EPS, compared to $(15.9) million in Q1 2025.
- Gross Margin Slightly Declined
- Gross margin for the quarter decreased to 79.3%, down from 79.7% a year ago.
- Decrease in Operating Expenses
- Total operating expenses decreased 5.0% to $54.6 million from $57.5 million in Q1 2025.
- Strong Cash Flow from Operations
- Operating cash flow increased to $7.2 million from $4.2 million in Q1 2025.
- Stable Cash Position
- Cash and cash equivalents at $9.5 million plus $42.3 million in marketable securities.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Competition
- Increased competition from various companies has eroded market share, as seen with lower sales of the flagship Lapiplasty System.
- Macroeconomic Headwinds
- Ongoing macroeconomic challenges, including inflation and consumer confidence, are anticipated to continue affecting demand for elective surgeries.
- Legal Challenges
- Multiple ongoing lawsuits, including those against Stryker and Zimmer, could have indefinite impacts on finances and operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.28
- Gross margin
- 79.3%
What they said about what is next.
Full-year 2026 revenue guidance remains at $202 million to $212 million, reflecting expected case volume growth amid product mix headwinds.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TMCI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever